Clinical Effectiveness of First‐Line Anti‐TNF Therapies and Second‐Line Anti‐TNF Therapy Post‐Vedolizumab Discontinuation in Patients With Ulcerative Colitis or Crohn's Disease: 638. (October 2019) - Bressler, Brian